Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zymeworks (ZYME) and Bioxcel Therapeutics (BTAI) with bullish sentiments.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks (ZYME)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Zymeworks today and set a price target of $46.00. The company’s shares closed last Thursday at $27.35.
According to TipRanks.com, Burns is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $39.75 average price target, which is a 51.3% upside from current levels. In a report issued on March 30, LifeSci Capital also maintained a Buy rating on the stock with a $34.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bioxcel Therapeutics (BTAI)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bioxcel Therapeutics today and set a price target of $5.00. The company’s shares closed last Thursday at $1.08.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of
Currently, the analyst consensus on Bioxcel Therapeutics is a Moderate Buy with an average price target of $7.67.
Read More on ZYME:
Disclaimer & DisclosureReport an Issue
- Zymeworks Bolsters Executive Team to Drive Next Phase of Growth
- Zymeworks appoints new Head of R&D and Chief Business Officer
- Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
- Zymeworks Names Kristin Stafford as New Chief Financial Officer
- Zymeworks appoints Kristin Stafford as CFO
